Myriad Genetics (MYGN) AI Stock Analysis

• Market Cap: $729.47M
• Dividend Yield: N/A
• Average Volume (3M): 1.55M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.80
• Revenue Growth: 3.83%
• EPS Growth: -137.31%
• Country: US
• Employees: 2,700
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.05
• Shares Outstanding: 93,044,624
• 10 Day Avg. Volume: 1,805,604
• 30 Day Avg. Volume: 1,547,973
• PEG Ratio: 0.18
• Price to Book (P/B): 1.77
• Price to Sales (P/S): 1.48
• P/FCF Ratio: -32.35
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 0.69
• Enterprise Value/Gross Profit: 0.97
• Enterprise Value/Ebitda: -1.61
• 1Y Price Target: $7.29
• Price Target Upside: -5.57% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8

• Rating: 52 Neutral
• Price Target: $6.00 ▼(-22.28% Downside)

Myriad Genetics' overall stock score reflects strong revenue growth and positive earnings call sentiment. However, significant challenges in profitability, cash flow management, and valuation weigh heavily on the score. The technical analysis shows short-term strength, but longer-term indicators suggest caution.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective pricing strategies, supporting long-term business expansion.

Strategic Focus on Cancer Care

Focusing on high-growth segments like cancer care can drive sustained growth and profitability by expanding the testing portfolio.

Securing $200 Million Term Loan

The loan provides liquidity and flexibility, enabling strategic investments and supporting long-term growth initiatives.

Negative Factors

Profitability Challenges

Ongoing profitability issues highlight cost control challenges, which may hinder long-term financial stability and growth.

GeneSight Revenue Impact

Policy changes affecting key products like GeneSight can reduce revenue streams and impact market position over the long term.

Cash Flow Management

Inefficiencies in cash generation can limit the company's ability to invest in growth opportunities and manage debt effectively.

Myriad Genetics Business Overview & Revenue Model

Company Description

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

How the Company Makes Money

Myriad Genetics generates revenue primarily through the sale of its genetic testing services. The company operates a fee-for-service model, where healthcare providers order tests for patients, and Myriad bills the insurers or patients directly. Key revenue streams include the hereditary cancer testing segment, which assesses genetic mutations in patients to evaluate their cancer risk, and the myRisk test that evaluates multiple cancer types simultaneously. Additionally, Myriad earns income from its pharmacogenomic tests that help determine how patients metabolize certain medications, enhancing treatment efficacy. The company has also established significant partnerships with various healthcare organizations and payers, which facilitates broader access to its tests and enhances its market presence. Factors contributing to earnings include increasing awareness and demand for genetic testing, advancements in technology, and the growing emphasis on personalized medicine.

Myriad Genetics Financial Statement Overview

Summary

Myriad Genetics shows strong revenue growth but faces significant challenges in profitability and cash flow management. The company has a solid gross profit margin, but negative net margins and cash flows indicate ongoing operational and financial hurdles. The balance sheet shows moderate leverage, but the negative return on equity suggests inefficiencies in generating returns.

Income Statement

Myriad Genetics shows a mixed performance in its income statement. The company has experienced a positive revenue growth rate of 19.2% in the TTM, indicating strong top-line growth. However, the company is struggling with profitability, as evidenced by negative net profit, EBIT, and EBITDA margins. The gross profit margin remains healthy at over 70%, but the significant negative net profit margin of -47.4% highlights ongoing challenges in controlling costs and achieving profitability.

Balance Sheet

The balance sheet of Myriad Genetics reflects moderate leverage with a debt-to-equity ratio of 0.40 in the TTM, which is manageable. However, the return on equity is negative, indicating that the company is not generating profits from its equity base. The equity ratio is not explicitly provided, but the company's equity position appears stable relative to its assets.

Cash Flow

The cash flow statement reveals challenges in cash generation, with negative operating and free cash flows in the TTM. Despite a significant improvement in free cash flow growth, the operating cash flow to net income ratio is negative, indicating inefficiencies in converting income into cash. The free cash flow to net income ratio is positive, suggesting some ability to generate cash relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	832.90M	837.60M	753.20M	678.40M	690.60M	557.00M
Gross Profit	586.70M	585.40M	517.00M	476.40M	493.00M	378.80M
EBITDA	-355.00M	-59.50M	-186.10M	-67.80M	14.10M	-123.40M
Net Income	-395.20M	-127.30M	-263.30M	-112.00M	-27.20M	-223.70M
Balance Sheet
Total Assets	677.30M	1.03B	1.15B	1.20B	1.32B	1.42B
Cash, Cash Equivalents and Short-Term Investments	74.40M	102.40M	140.90M	114.90M	339.80M	150.70M
Total Debt	154.60M	140.30M	152.10M	145.00M	92.30M	0.00
Total Liabilities	289.20M	326.50M	363.30M	312.90M	352.90M	537.80M
Stockholders Equity	388.10M	701.10M	783.20M	885.80M	967.80M	881.00M
Cash Flow
Free Cash Flow	-50.00M	-38.40M	-184.20M	-151.60M	600.00K	-40.10M
Operating Cash Flow	-22.60M	-8.70M	-110.90M	-106.30M	18.60M	-26.90M
Investing Cash Flow	-13.60M	-11.90M	31.90M	-77.50M	274.40M	61.60M
Financing Cash Flow	15.20M	-7.40M	152.90M	-8.00M	-150.60M	-1.00M

Myriad Genetics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.72
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYGN, the sentiment is Positive. The current price of 7.72 is above the 20-day moving average (MA) of 7.11, above the 50-day MA of 5.91, and below the 200-day MA of 8.46, indicating a neutral trend. The MACD of 0.52 indicates Negative momentum. The RSI at 67.44 is Neutral, neither overbought nor oversold. The STOCH value of 73.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MYGN.

Myriad Genetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FLGT	63 Neutral	676.46M	-13.25	-4.57%	―	4.31%	69.57%
CSTL	59 Neutral	657.62M	-63.73	-2.08%	―	20.40%	-165.41%
CDNA	58 Neutral	801.60M	14.75	15.79%	―	14.72%	―
MYGN	52 Neutral	$729.47M	―	-70.03%	―	3.83%	-137.31%
PSNL	52 Neutral	537.38M	-4.76	-47.85%	―	0.36%	22.13%
NEO	50 Neutral	1.02B	-9.65	-12.18%	―	9.70%	-30.94%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Myriad Genetics Corporate Events

Myriad Genetics Appoints Ben R. Wheeler as CFO

On August 18, 2025, Myriad Genetics announced the appointment of Ben R. Wheeler as the new Chief Financial Officer, effective August 16, 2025, following the departure of Scott J. Leffler from the role. Wheeler, who has been with the company for over 13 years, brings extensive financial expertise and leadership experience, which is expected to support Myriad’s growth strategy. The company also reaffirmed its financial guidance for the full year 2025, indicating confidence in its strategic direction.

Myriad Genetics Secures $200 Million Credit Agreement

On July 31, 2025, Myriad Genetics entered into a $200 million credit agreement with OrbiMed Royalty & Credit Opportunities IV, LP, which includes a $125 million initial loan and an option for an additional $75 million until June 30, 2027. This credit facility, secured by Myriad’s assets, will support the company’s working capital needs and growth strategy, replacing its previous ABL facility.